The main aim of this study was to evaluate the effectiveness of 18F-fluorodeoxyglucose (18FDG) positron emission tomography/computerized tomography (PET/CT) parameters in predicting the Kristen rat sarcoma viral oncogene(KRAS) mutation status of patients with colon cancer.
Materials and Methods:
Between April 2013 and December 2020, 79 patients who were diagnosed with colon cancer by colonoscopy underwent staging 18FDG PET/CT with this diagnosis and met all the inclusion criteria were included in this study. Clinical and prognostic features and also imaging (18FDG PET/CT and magnetic resonance imaging) reports of the patients were collected and analyzed retrospectively.
Results:
KRAS mutation was seen in 32 of patients (40.5%). No significant difference was observed between KRAS mutant and wild-type patients in terms of clinical features (tumor location, findings regarding metastasis, T stage, and tumor differentiation grade in patients who underwent surgery) and overall survival. Progression-free survival was significantly shorter in KRAS mutant patients (p = 0.018). Primary tumor standardized uptake value (SUVmean) was significantly higher in KRAS mutant cases in the whole group (p = 0.024) and in patients in whom KRAS analysis was performed only in the primary lesion (p = 0.036). The cutoff value for predicting KRAS mutation status was 7.01 g/mL (area under the curve [AUC]: 0.650, confidence interval [CI] 95%, 0.56–0.74).
Conclusions:
When colon and rectal cancer cases were evaluated separately, the primary tumor SUVmean value was significantly higher in KRAS mutant colon cancer cases. However, its effectiveness in predicting KRAS mutation status was low, similar to other parameters in the literature.
Get full access to this article
View all access options for this article.
References
1.
SiegelRL, MillerKD, JemalA. Cancer statistics, 2020. CA Cancer J Clin, 2020; 70(1):7–30; doi: 10.3322/caac.21590
2.
Van CutsemE, CervantesA, NordlingerB, et al.ESMO Guidelines Working Group. Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2014; 25 Suppl 3(Suppl 3):iii1–9; doi: 10.1093/annonc/mdu260
3.
ArgilésG, TaberneroJ, LabiancaR, et al.ESMO Guidelines Committee. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2020; 31(10):1291–1305; doi: 10.1016/j.annonc.2020.06.022
4.
LeeYC, LeeYL, ChuangJP, et al.Differences in survival between colon and rectal cancer from SEER data. PLoS One, 2013; 8(11):e78709; doi: 10.1371/journal.pone.0078709
5.
BenedixF, KubeR, MeyerF, et al.Colon/Rectum Carcinomas (Primary Tumor) Study Group. Comparison of 17,641 patients with right- and left-sided colon cancer: Differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum, 2010; 53(1):57–64; doi: 10.1007/DCR.0b013e3181c703a4
6.
Glynne-JonesR, WyrwiczL, TiretE, et al.ESMO Guidelines Committee. Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2017; 28(suppl_4):iv22–iv40; doi: 10.1093/annonc/mdx224
7.
AfrăsânieVA, MarincaMV, Alexa-StratulatT, et al.KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer - practical implications for the clinician. Radiol Oncol, 2019; 53(3):265–274; doi: 10.2478/raon-2019-0033
8.
ZhuG, PeiL, XiaH, et al.Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. Mol Cancer, 2021; 20(1):143; doi: 10.1186/s12943-021-01441-4
9.
TabibzadehA, TameshkelFS, MoradiY, et al.Signal transduction pathway mutations in gastrointestinal (GI) cancers: A systematic review and meta-analysis. Sci Rep, 2020; 10(1):18713; doi: 10.1038/s41598-020-73770-1
10.
StricklerJH, YoshinoT, StevinsonK, et al.Prevalence of KRAS G12C mutation and co-mutations and associated clinical outcomes in patients with colorectal cancer: A systematic literature review. Oncologist, 2023; 28(11):e981–e994; doi: 10.1093/oncolo/oyad138
11.
BensonAB, VenookAP, Al-HawaryMM, et al.Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 2021; 19(3):329–359; doi: 10.6004/jnccn.2021.0012
12.
SepulvedaAR, HamiltonSR, AllegraCJ, et al.Molecular biomarkers for the evaluation of colorectal cancer: Guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. J Clin Oncol, 2017; 35(13):1453–1486; doi: 10.1200/JCO.2016.71.9807
13.
LiX, YeJ, WangJ, et al.First-in-humans PET imaging of KRASG12C mutation status in non-small cell lung and colorectal cancer patients using [18F]PFPMD. J Nucl Med, 2023; 64(12):1880–1888; doi: 10.2967/jnumed.123.265715
14.
HeP, ZouY, QiuJ, et al.Pretreatment 18F-FDG PET/CT imaging predicts the KRAS/NRAS/BRAF gene mutational status in colorectal cancer. J Oncol, 2021; 2021:6687291; doi: 10.1155/2021/6687291
15.
LeeH, MoonSH, HongJY, et al.A machine learning approach using FDG PET-based radiomics for prediction of tumor mutational burden and prognosis in stage IV colorectal cancer. Cancers (Basel), 2023; 15(15):3841; doi: 10.3390/cancers15153841
16.
LiuH, LiangZ, ZhouC, et al.Mutant KRAS triggers functional reprogramming of tumor-associated macrophages in colorectal cancer. Signal Transduct Target Ther, 2021; 6(1):144; doi: 10.1038/s41392-021-00534-2
17.
SakashitaM, AoyamaN, MinamiR, et al.Glut1 expression in T1 and T2 stage colorectal carcinomas: Its relationship to clinicopathological features. Eur J Cancer, 2001; 37(2):204–209; doi: 10.1016/s0959-8049(00)00371-3
Levin-SparenbergE, BylsmaLC, LoweK, et al.A systematic literature review and meta-analysis describing the prevalence of KRAS, NRAS, and BRAF gene mutations in metastatic colorectal cancer. Gastroenterology Res, 2020; 13(5):184–198; doi: 10.1474/0/gr1167
20.
BaldusSE, SchaeferKL, EngersR, et al.Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res, 2010; 16(3):790–799; doi: 10.1158/1078-0432.CCR-09-2446
21.
SungH, FerlayJ, SiegelRL, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021; 71(3):209–249; doi: 10.3322/caac.21660
22.
BylsmaLC, DeanR, LoweK, et al.The incidence of infusion reactions associated with monoclonal antibody drugs targeting the epidermal growth factor receptor in metastatic colorectal cancer patients: A systematic literature review and meta-analysis of patient and study characteristics. Cancer Med, 2019; 8(12):5800–5809; doi: 10.1002/cam4.2413
23.
García-AlfonsoP, LièvreA, LoupakisF, et al.Systematic review of randomised clinical trials and observational studies for patients with RAS wild-type or BRAFV600E-mutant metastatic and/or unresectable colorectal cancer. Crit Rev Oncol Hematol, 2022; 173:103646; doi: 10.1016/j.critrevonc.2022
KwakMS, ChaJM, ChoYH, et al.Clinical predictors for KRAS codon 13 mutations in patients with colorectal cancer. J Clin Gastroenterol, 2018; 52(5):431–436; doi: 10.1097/MCG.0000000000000809
26.
PeetersM, DouillardJY, Van CutsemE, et al.Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: Assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol, 2013; 31(6):759–765; doi: 10.1200/JCO.2012.45.1492
27.
ShadyW, PetreEN, VakianiE, et al.KRAS mutation is a marker of worse oncologic outcomes after percutaneous radiofrequency ablation of colorectal liver metastases. Oncotarget, 2017; 8(39):66117–66127; doi: 10.1863/2/oncotarget.19806
28.
VautheyJN, ZimmittiG, KopetzSE, et al.RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg, 2013; 258(4):619–626; discussion 626-7; doi: 10.1097/SLA.0b013e3182a5025a
29.
KawadaK, NakamotoY, KawadaM, et al.Relationship between 18F-fluorodeoxyglucose accumulation and KRAS/BRAF mutations in colorectal cancer. Clin Cancer Res, 2012; 18(6):1696–1703; doi: 10.1158/1078-0432.CCR-11-1909
30.
IwamotoM, KawadaK, NakamotoY, et al.Regulation of 18F-FDG accumulation in colorectal cancer cells with mutated KRAS. J Nucl Med, 2014; 55(12):2038–2044; doi: 10.2967/jnumed.114.142927
31.
KawadaK, TodaK, NakamotoY, et al.Relationship Between 18F-FDG PET/CT Scans and KRAS mutations in metastatic colorectal cancer. J Nucl Med, 2015; 56(9):1322–1327; doi: 10.2967/jnumed.115.160614
32.
ChenSW, ChiangHC, ChenWT, et al.Correlation between PET/CT parameters and KRAS expression in colorectal cancer. Clin Nucl Med, 2014; 39(8):685–689; doi: 10.1097/RLU.0000000000000481
33.
ChoA, JoK, HwangSH, et al.Correlation between KRAS mutation and 18F-FDG uptake in stage IV colorectal cancer. Abdom Radiol (NY), 2017; 42(6):1621–1626; doi: 10.1007/s00261-017-1054-2
34.
ArslanE, AksoyT, GürsuRU, et al.The prognostic value of 18F-FDG PET/CT and KRAS mutation in colorectal cancers. Mol Imaging Radionucl Ther, 2020; 29(1):17–24; doi: 10.4274/mirt.galenos.2019.33866
35.
ChenSW, LinCY, HoCM, et al.Genetic alterations in colorectal cancer have different patterns on 18F-FDG PET/CT. Clin Nucl Med, 2015; 40(8):621–626; doi: 10.1097/RLU.0000000000000830
36.
OnerAO, BudakES, YıldırımS, et al.The value of 18FDG PET/CT parameters, hematological parameters and tumor markers in predicting KRAS oncogene mutation in colorectal cancer. Hell J Nucl Med, 2017; 20(2):160–165; doi: 10.1967/s002449910557
37.
KrikelisD, SkouraE, KotoulaV, et al.Lack of association between KRAS mutations and 18F-FDG PET/CT in Caucasian metastatic colorectal cancer patients. Anticancer Res, 2014; 34(5):2571–2579.
38.
SchmollHJ, Van CutsemE, SteinA, et al.ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol, 2012; 23(10):2479–2516; doi: 10.1093/annonc/mds236
39.
BruléSY, JonkerDJ, KarapetisCS, et al.Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. Eur J Cancer, 2015; 51(11):1405–1414; doi: 10.1016/j.ejca.2015.03.015
40.
PengJ, LvJ, PengJ. KRAS mutation is predictive for poor prognosis in rectal cancer patients with neoadjuvant chemoradiotherapy: A systemic review and meta-analysis. Int J Colorectal Dis, 2021; 36(8):1781–1790; doi: 10.1007/s00384-021-03911-z
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
